Nitrazepam Richter

Nitrazepam, the active ingredient in Nitrazepam Richter, is a benzodiazepine presented as a tablet for oral use. It is prescribed for insomnia, anxiety disorders and seizure disorders in adult patients.

GNH USA supplies Nitrazepam Richter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nitrazepam belongs to the benzodiazepine class and acts on the central nervous system to modulate GABA activity, making it useful for several neuro‑psychiatric conditions.

Insomnia: helps initiate and maintain sleep in patients with difficulty sleeping. Anxiety disorders: reduces excessive worry and tension. Seizure disorders: provides adjunctive control of certain seizure types.

Nitrazepam may cause a range of adverse reactions, from mild to severe. Awareness of these effects helps clinicians monitor patients appropriately.

Common Side Effects: - Drowsiness - Fatigue - Dizziness - Impaired coordination - Memory impairment - Headache

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Paradoxical reactions such as agitation - Suicidal ideation or behavior - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Dependence or withdrawal syndrome

When prescribing nitrazepam, several safety considerations should be observed.

Assess renal and hepatic function: adjust use if impairment is present. Avoid abrupt discontinuation: taper dose to prevent withdrawal. Use caution in elderly patients: increased sensitivity to sedation and falls. Avoid concomitant alcohol or CNS depressants: risk of additive sedation. Monitor for depression or suicidal thoughts: especially during early treatment. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nitrazepam can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Other CNS depressants (opioids, barbiturates, alcohol): may cause profound sedation or respiratory depression. - Strong CYP3A4 inhibitors (ketoconazole, itraconazole): increase nitrazepam plasma levels. - Concurrent benzodiazepines: risk of excessive sedation and dependence.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (rifampin, carbamazepine): may reduce therapeutic effect. - Selective serotonin reuptake inhibitors (SSRIs): may enhance central nervous system depression. - Antihistamines: can increase drowsiness. - Antiepileptic drugs (phenytoin): may alter seizure control. - Antihypertensives: additive hypotensive effect possible.